

Aditya Bardia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9519893/publications.pdf>

Version: 2024-02-01

252
papers

14,167
citations

46984

47
h-index

23514

111
g-index

256
all docs

256
docs citations

256
times ranked

18560
citing authors

#	ARTICLE	IF	CITATIONS
1	NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. <i>British Journal of Cancer</i> , 2022, 126, 514-520.	2.9	19
2	Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor- ⁺ positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. <i>Clinical Cancer Research</i> , 2022, 28, 821-830.	3.2	26
3	Antibody- ⁺ drug conjugates: Smart chemotherapy delivery across tumor histologies. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 165-182.	157.7	132
4	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 12-23.	0.8	75
5	Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells. <i>Nature Nanotechnology</i> , 2022, 17, 98-106.	15.6	135
6	Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. <i>Cancer Cell</i> , 2022, 40, 103-108.e2.	7.7	30
7	AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2- ⁺ advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210839.	1.4	16
8	Abstract P3-09-11: Clinical characteristics associated with BRCA1/2 mutations identified on routine tumor tissue genotyping in metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P3-09-11-P3-09-11.	0.4	0
9	Abstract OT2-11-08: AMEERA-5 : A randomized, double-blind phase 3 study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer. <i>Cancer Research</i> , 2022, 82, OT2-11-08-OT2-11-08.	0.4	0
10	Abstract OT2-11-09: Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician's choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2- EBC). <i>Cancer Research</i> , 2022, 82, OT2-11-09-OT2-11-09.	0.4	5
11	Abstract PD13-03: Ribociclib, everolimus, exemestane triplet therapy in HR+/HER2- ⁺ advanced breast cancer after progression on a CDK4/6 inhibitor: Final efficacy, safety, and biomarker results from TRINITI-1. <i>Cancer Research</i> , 2022, 82, PD13-03-PD13-03.	0.4	1
12	Abstract OT2-24-03: Phase II study of a PARP inhibitor in metastatic breast cancer with somatic BRCA1/2 mutations identified by cell-free DNA: Genotyping based clinical trial. <i>Cancer Research</i> , 2022, 82, OT2-24-03-OT2-24-03.	0.4	0
13	Abstract PD6-08: Exploring the interplay among ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS). <i>Cancer Research</i> , 2022, 82, PD6-08-PD6-08.	0.4	0
14	Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC). <i>Cancer Research</i> , 2022, 82, P2-07-02-P2-07-02.	0.4	1
15	Abstract OT2-11-03: AMEERA-1 : Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) PIK3CA-mutated advanced breast cancer. <i>Cancer Research</i> , 2022, 82, OT2-11-03-OT2-11-03.	0.4	0
16	Abstract P5-16-01: Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC). <i>Cancer Research</i> , 2022, 82, P5-16-01-P5-16-01.	0.4	0
17	Abstract GS2-02: Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial. <i>Cancer Research</i> , 2022, 82, GS2-02-GS2-02.	0.4	15
18	Abstract PD2-03: Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus palbociclib or ribociclib. <i>Cancer Research</i> , 2022, 82, PD2-03-PD2-03.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation. Cancer Research, 2022, 82, P1-18-22-P1-18-22.	0.4	0
20	Abstract P1-14-02: Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER, part 1). Cancer Research, 2022, 82, P1-14-02-P1-14-02.	0.4	1
21	Abstract P2-01-01: Genetic alterations detected by circulating tumor DNA (ctDNA) in HER2-low metastatic breast cancer (MBC). Cancer Research, 2022, 82, P2-01-01-P2-01-01.	0.4	0
22	Abstract PD14-04: Circulating tumor DNA characterization of invasive lobular carcinoma in patients with metastatic breast cancer. Cancer Research, 2022, 82, PD14-04-PD14-04.	0.4	0
23	Abstract P4-12-08: Accuracy of Patient Self-Reported Breast Cancer Disease Characteristics Compared to the Medical Record in a Trial of the Outcomes4MeDigital Health App. Cancer Research, 2022, 82, P4-12-08-P4-12-08.	0.4	0
24	Abstract OT1-12-05: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer. Cancer Research, 2022, 82, OT1-12-05-OT1-12-05.	0.4	0
25	Abstract P1-18-05: Early changes in circulating tumor DNA and its effect on clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib: Genotyping results from POLARIS. Cancer Research, 2022, 82, P1-18-05-P1-18-05.	0.4	1
26	Abstract P5-16-15: Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). Cancer Research, 2022, 82, P5-16-15-P5-16-15.	0.4	2
27	Abstract P3-23-02: Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer receiving CDK 4/6 inhibitors. Cancer Research, 2022, 82, P3-23-02-P3-23-02.	0.4	0
28	Abstract P5-16-07: Assessment of sacituzumab govitecan (SG) in Black patients (pts) from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC). Cancer Research, 2022, 82, P5-16-07-P5-16-07.	0.4	0
29	Abstract OT2-11-04: Ameer-1 Arm 5: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with abemaciclib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Cancer Research, 2022, 82, OT2-11-04-OT2-11-04.	0.4	0
30	Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies. Cancer Research, 2022, 82, PD2-05-PD2-05.	0.4	2
31	Abstract P4-10-09: Patient-centered dosing: Oncologists'™ perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC). Cancer Research, 2022, 82, P4-10-09-P4-10-09.	0.4	2
32	Abstract P2-14-17: A phase 1b study of PVX-410 vaccine in combination with pembrolizumab in metastatic triple negative breast cancer (mTNBC). Cancer Research, 2022, 82, P2-14-17-P2-14-17.	0.4	4
33	Abstract PD13-06: Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole + palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study. Cancer Research, 2022, 82, PD13-06-PD13-06.	0.4	6
34	Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2+ Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clinical Cancer Research, 2022, 28, 851-859.	3.2	90
35	Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Research and Treatment, 2022, 195, 127-139.	1.1	15
36	VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results. Clinical Cancer Research, 2022, 28, 3256-3267.	3.2	28

#	ARTICLE	IF	CITATIONS
37	Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 3246-3256.	0.8	190
38	Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan. <i>Oncologist</i> , 2022, 27, 637-645.	1.9	12
39	Utilizing Natural Language Processing (NLP) to identify breast cancer associated-lung metastases from pathology reports to delineate characteristics and challenges of this common site of breast cancer recurrence.. <i>Journal of Clinical Oncology</i> , 2022, 40, e13592-e13592.	0.8	0
40	Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer phase 3 ASCENT study subanalysis. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	25
41	Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 512-512.	0.8	22
42	Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2- advanced breast cancer (ABC) in MONALEESA(ML)-2.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1017-1017.	0.8	5
43	Abstract 5248: CDK4/6 inhibition (CDK4/6i) is effective in the real-world setting for hormone receptor-positive metastatic breast cancer (HR+ MBC) with <i>ESR1</i> mutations and fusions. <i>Cancer Research</i> , 2022, 82, 5248-5248.	0.4	0
44	TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS623-TPS623.	0.8	13
45	Adjuvant trastuzumab and vinorelbine (TV) for early-stage HER2+ breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e12521-e12521.	0.8	0
46	Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2- eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 589-589.	0.8	20
47	Sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1071-1071.	0.8	7
48	Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy. <i>JCO Precision Oncology</i> , 2022, , .	1.5	1
49	Abstract CT517: Amcenestrant, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/HER2- advanced breast cancer (aBC): combined biomarker analyses from a Phase 1/2 study in postmenopausal women and a Phase 1 study in postmenopausal Japanese women. <i>Cancer Research</i> , 2022, 82, CT517-CT517.	0.4	0
50	Abstract 2638: Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triple-negative breast cancer (TNBC): Translational investigation. <i>Cancer Research</i> , 2022, 82, 2638-2638.	0.4	14
51	Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS624-TPS624.	0.8	2
52	Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator's choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 1100-1100.	0.8	6
53	Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (Pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA1001-LBA1001.	0.8	68
54	Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 1015-1015.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Baseline preferences for digital information engagement in patients with breast cancer by age and status of diagnosis.. Journal of Clinical Oncology, 2022, 40, e24119-e24119.	0.8	0
56	AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer. Nature Communications, 2022, 13, .	5.8	24
57	Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. Oncologist, 2021, 26, 49-55.	1.9	18
58	Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 109-117.	2.3	10
59	Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates. Oncology, 2021, 35, 249-254.	0.4	14
60	Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3404-3413.	3.2	10
61	Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer. Oncotarget, 2021, 12, 63-65.	0.8	1
62	Abstract PS7-02: The relationship of established breast cancer risk factors with breast cancer subtypes. , 2021, , .		0
63	Abstract OT-03-09: Trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator's choice of chemotherapy in patients with hormone receptor-positive (HR+), HER2 low metastatic breast cancer whose disease has progressed on endocrine therapy in the metastatic setting: A randomized, global phase 3 trial (DESTINY-Breast06). Cancer Research, 2021, 81, OT-03-09-OT-03-09.	0.4	11
64	Abstract PD9-07: Genomic landscape of metastatic breast cancer (MBC): Comprehensive cell-free DNA analysis from over 10,000 patients and comparison with primary breast cancer. , 2021, , .		0
65	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist, 2021, 26, 514-522.	1.9	18
66	Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). Clinical Cancer Research, 2021, 27, 4177-4185.	3.2	47
67	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2021, 384, 1529-1541.	13.9	601
68	Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degradar, in ER-Positive, HER2-Negative Advanced Breast Cancer. Journal of Clinical Oncology, 2021, 39, 1360-1370.	0.8	69
69	Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2021, 39, 1005-1005.	0.8	8
70	Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).. Journal of Clinical Oncology, 2021, 39, 1004-1004.	0.8	28
71	Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2021, 39, 1011-1011.	0.8	9
72	Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. Oncologist, 2021, 26, e1427-e1433.	1.9	11

#	ARTICLE	IF	CITATIONS
73	Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. <i>Cancer Discovery</i> , 2021, 11, 2474-2487.	7.7	92
74	Landscape of GATA3 mutations identified from circulating tumor DNA clinical testing and their impact on disease outcomes in estrogen receptor-positive (ER+) metastatic breast cancers treated with endocrine therapies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1065-1065.	0.8	1
75	Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 1017-1017.	0.8	24
76	AMEERA-5: A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS1104-TPS1104.	0.8	2
77	Phase II multicenter study of talazoparib for somatic <i>BRCA1/2</i> mutant metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS1110-TPS1110.	0.8	2
78	persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2- LA/mBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS1103-TPS1103.	0.8	3
79	Uncovering the differential impact of <i>ESR1</i> and <i>PIK3CA</i> codon variants on the clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2021, 39, 1033-1033.	0.8	3
80	TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS603-TPS603.	0.8	4
81	Feasibility of integrating the Outcomes4Me smartphone navigation application into the care of breast cancer patients (FIONA).. <i>Journal of Clinical Oncology</i> , 2021, 39, 1570-1570.	0.8	1
82	Impact of multidisciplinary severe immunotherapy complication service on outcomes for cancer patients receiving immune checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2654-2654.	0.8	0
83	Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) operable breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 577-577.	0.8	14
84	Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. <i>Oncologist</i> , 2021, 26, 685-693.	1.9	3
85	Evaluation of endocrine resistance using <i>ESR1</i> genotyping of circulating tumor cells and plasma DNA. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 43-52.	1.1	8
86	Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 679-686.	2.9	31
87	Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy. <i>Nature Cancer</i> , 2021, 2, 658-671.	5.7	34
88	Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. <i>Oncologist</i> , 2021, 26, 827-834.	1.9	28
89	Locally Recurrent Secretory Carcinoma of the Breast with <i>NTRK3</i> Gene Fusion. <i>Oncologist</i> , 2021, 26, 818-824.	1.9	8
90	Relationship of established risk factors with breast cancer subtypes. <i>Cancer Medicine</i> , 2021, 10, 6456-6467.	1.3	45

#	ARTICLE	IF	CITATIONS
91	Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2021, 11, 2436-2445.	7.7	69
92	Genomic Profiling of Premenopausal HR+ and HER2+ Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. <i>JCO Precision Oncology</i> , 2021, 5, 1408-1420.	1.5	15
93	Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 103.	2.3	17
94	ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 85.	2.2	124
95	A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2021, 17, 3911-3924.	1.1	9
96	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886.		9
97	The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1361-1370.	3.2	25
98	Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, , 1-8.	2.3	36
99	Antibody drug conjugates for patients with breast cancer. <i>Current Problems in Cancer</i> , 2021, 45, 100795.	1.0	3
100	A careful reassessment of anthracycline use in curable breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 134.	2.3	25
101	Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. <i>Nature Communications</i> , 2021, 12, 5954.	5.8	35
102	CTIM-02. PHASE II STUDY OF IPILIMUMAB AND NIVOLUMAB IN LEPTOMENINGEAL CARCINOMATOSIS. <i>Neuro-Oncology</i> , 2021, 23, vi49-vi49.	0.6	0
103	Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with <i>RAS/RAF</i> Alterations. <i>Oncologist</i> , 2020, 25, e160-e169.	1.9	55
104	Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers. <i>Cancer Discovery</i> , 2020, 10, 86-103.	7.7	100
105	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1246-1262.	1.5	16
106	The Art of Oncology: COVID-19 Era. <i>Oncologist</i> , 2020, 25, 997-1000.	1.9	6
107	Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094306.	1.4	44
108	POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone-receptor-positive advanced breast cancer. <i>Future Oncology</i> , 2020, 16, 2475-2485.	1.1	9

#	ARTICLE	IF	CITATIONS
109	The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. <i>Journal of Oncology Pharmacy Practice</i> , 2020, , 107815522097175.	0.5	2
110	Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 227-241.	0.4	24
111	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020, 395, 1907-1918.	6.3	1,395
112	Novel antibody-drug conjugates for triple negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091598.	1.4	74
113	Identification of Somatic Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4852-4862.	3.2	12
114	Patient Preferences for Use of Archived Biospecimens from Oncology Trials When Adequacy of Informed Consent Is Unclear. <i>Oncologist</i> , 2020, 25, 78-86.	1.9	7
115	Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. <i>Lancet, The</i> , 2020, 395, 817-827.	6.3	260
116	Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic. <i>New England Journal of Medicine</i> , 2020, 383, 262-272.	13.9	12
117	Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis. <i>Science</i> , 2020, 367, 1468-1473.	6.0	214
118	Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. <i>Nature Biotechnology</i> , 2020, 38, 420-425.	9.4	48
119	Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion <i>BRCA</i> Mutations among Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2546-2555.	3.2	33
120	Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. <i>Clinical Cancer Research</i> , 2020, 26, 2838-2848.	3.2	403
121	Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer. <i>BMC Cancer</i> , 2020, 20, 347.	1.1	10
122	TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer. <i>Future Oncology</i> , 2020, 16, 705-715.	1.1	62
123	Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2 ⁺ Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6417-6428.	3.2	11
124	Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 1009-1009.	0.8	34
125	A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1023-1023.	0.8	29
126	Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC). <i>Journal of Clinical Oncology</i> , 2020, 38, 1066-1066.	0.8	13

#	ARTICLE	IF	CITATIONS
127	Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).. Journal of Clinical Oncology, 2020, 38, 1070-1070.	0.8	12
128	Comparison of the cell-free DNA genomics in patients with metastatic breast cancer (MBC) who develop brain metastases versus those without brain metastases.. Journal of Clinical Oncology, 2020, 38, 1094-1094.	0.8	1
129	Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).. Journal of Clinical Oncology, 2020, 38, 505-505.	0.8	34
130	Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER).. Journal of Clinical Oncology, 2020, 38, 531-531.	0.8	3
131	Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase I/II study.. Journal of Clinical Oncology, 2020, 38, 6081-6081.	0.8	4
132	Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study.. Journal of Clinical Oncology, 2020, 38, TPS1100-TPS1100.	0.8	16
133	KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2020, 38, TPS596-TPS596.	0.8	12
134	Phase II trial of a PARP inhibitor in somatic BRCA mutant metastatic breast cancer.. Journal of Clinical Oncology, 2020, 38, TPS1113-TPS1113.	0.8	3
135	Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC).. Journal of Clinical Oncology, 2020, 38, 1052-1052.	0.8	0
136	Highlights in metastatic breast cancer from the European Society for Medical Oncology Virtual Congress 2020: commentary. Clinical Advances in Hematology and Oncology, 2020, 18 Suppl 17, 20-23.	0.3	0
137	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology, The, 2019, 20, 1226-1238.	5.1	76
138	EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. Future Oncology, 2019, 15, 3209-3218.	1.1	43
139	Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. Npj Precision Oncology, 2019, 3, 18.	2.3	25
140	Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. Clinical Breast Cancer, 2019, 19, 399-404.	1.1	27
141	Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. New England Journal of Medicine, 2019, 381, 307-316.	13.9	656
142	Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy. Breast Cancer Research and Treatment, 2019, 176, 617-624.	1.1	7
143	Clinical Validation of a Cell-Free DNA Gene Panel. Journal of Molecular Diagnostics, 2019, 21, 632-645.	1.2	15
144	Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer. Lancet Oncology, The, 2019, 20, 746-748.	5.1	5

#	ARTICLE	IF	CITATIONS
145	Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 649-658.	1.1	5
146	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. <i>Nature Communications</i> , 2019, 10, 1373.	5.8	252
147	CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions. <i>Current Oncology Reports</i> , 2019, 21, 25.	1.8	122
148	Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 741-751.	13.9	542
149	Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer. <i>Current Medical Research and Opinion</i> , 2019, 35, 73-80.	0.9	20
150	Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. <i>Nature Cell Biology</i> , 2019, 21, 190-202.	4.6	384
151	Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 107-112.	1.9	8
152	Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2 ⁺ advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITY-1): Efficacy, safety, and biomarker results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1016-1016.	0.8	35
153	In-depth gene expression analysis of premenopausal patients with HR+/HER2 ⁺ advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1018-1018.	0.8	5
154	Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1028-1028.	0.8	5
155	Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2- metastatic breast cancer (mBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1054-1054.	0.8	6
156	A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1057-1057.	0.8	27
157	HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 502-502.	0.8	65
158	Phase 1/2 dose-escalation and expansion study investigating SAR439859 +/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2- metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS1105-TPS1105.	0.8	1
159	Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2 ⁺ locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS1108-TPS1108.	0.8	2
160	KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor ⁺ positive, human epidermal growth factor receptor 2 ⁺ negative (ER+/HER2 ⁺) breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS601-TPS601.	0.8	10
161	Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2 ⁺ advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA1008-LBA1008.	0.8	19
162	Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 354-354.	0.8	67

#	ARTICLE	IF	CITATIONS
163	Flu vaccination rate of patients with severe immune-related adverse events.. Journal of Clinical Oncology, 2019, 37, e18234-e18234.	0.8	1
164	EMERALD: A randomized, open label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901) versus investigator's choice (IC) of endocrine therapy (ET) for ER+/HER2- advanced breast cancer (BC) following CDK4/6 inhibitor (CDK4/6i) therapy.. Journal of Clinical Oncology, 2019, 37, TPS1104-TPS1104.	0.8	1
165	Clinical outcomes of patients with stage IV cancer receiving immune checkpoint inhibitors in the inpatient setting.. Journal of Clinical Oncology, 2019, 37, 6634-6634.	0.8	2
166	Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer. Clinical Cancer Research, 2018, 24, 2981-2983.	3.2	5
167	AR Expression in Breast Cancer CTCs Associates with Bone Metastases. Molecular Cancer Research, 2018, 16, 720-727.	1.5	68
168	Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer. Cancer Discovery, 2018, 8, 336-353.	7.7	32
169	Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. Journal of Clinical Oncology, 2018, 36, 3459-3465.	0.8	79
170	Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. Journal of Clinical Oncology, 2018, 36, 3126-3133.	0.8	52
171	Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer. New England Journal of Medicine, 2018, 379, 1946-1953.	13.9	4
172	Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. Breast Cancer Research and Treatment, 2018, 172, 733-740.	1.1	15
173	Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncology, The, 2018, 19, 904-915.	5.1	648
174	Research Biopsies: An Integrative Review of the Experiences of Patients With Cancer. Clinical Journal of Oncology Nursing, 2018, 22, E71-E77.	0.3	1
175	Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. Npj Breast Cancer, 2018, 4, 10.	2.3	95
176	Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. Breast Cancer Research and Treatment, 2018, 171, 111-120.	1.1	38
177	A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. Cancer Discovery, 2018, 8, 1286-1299.	7.7	85
178	Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC).. Journal of Clinical Oncology, 2018, 36, 1004-1004.	0.8	14
179	Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009).. Journal of Clinical Oncology, 2018, 36, 1040-1040.	0.8	11
180	Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer.. Journal of Clinical Oncology, 2018, 36, 12097-12097.	0.8	1

#	ARTICLE	IF	CITATIONS
181	Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.. Journal of Clinical Oncology, 2018, 36, 2546-2546.	0.8	37
182	Cost of inpatient admissions for immune-related adverse effects from immune checkpoint inhibitor therapy: A single center experience.. Journal of Clinical Oncology, 2018, 36, 3060-3060.	0.8	4
183	Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance.. Journal of Clinical Oncology, 2018, 36, 3096-3096.	0.8	4
184	Breast Cancer Index (BCI) and prediction of pathological complete response (pCR) to neoadjuvant chemotherapy in estrogen receptor positive (ER+) breast cancer.. Journal of Clinical Oncology, 2018, 36, 576-576.	0.8	2
185	A systematic literature review of the clinical prognosis of HR+/HER2- advanced or metastatic breast cancer with and without PIK3CA mutation.. Journal of Clinical Oncology, 2018, 36, e13037-e13037.	0.8	2
186	Inpatient admissions related to immune-related adverse effects (irAE) among patients treated with immune checkpoint inhibitors for advanced malignancy: A tsunami is coming, but are we ready?. Journal of Clinical Oncology, 2018, 36, 127-127.	0.8	10
187	Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis.. Journal of Clinical Oncology, 2018, 36, 1047-1047.	0.8	1
188	Patient attitudes towards biobanks and preferences for use of archived biospecimens.. Journal of Clinical Oncology, 2018, 36, e18612-e18612.	0.8	0
189	Healthcare medical costs among post-menopausal women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) managed with systemic therapy following CDK 4/6 inhibitor (CDKi) in the real-world setting.. Journal of Clinical Oncology, 2018, 36, 1067-1067.	0.8	0
190	Molecular alterations in the Ras-Raf-Erk (MAPK) pathway in metastatic hormone receptor positive (HR+)/HER2- breast cancer: Incidence and impact on clinical outcomes.. Journal of Clinical Oncology, 2018, 36, 1021-1021.	0.8	0
191	Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2018, 36, 1020-1020.	0.8	10
192	A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clinical Cancer Research, 2017, 23, 4035-4045.	3.2	104
193	Sacituzumab govitecan (IMMUâ€132), an antiâ€Tropâ€2â€SNâ€38 antibodyâ€drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer, 2017, 123, 3843-3854.	2.0	145
194	SWISH-ing steroids: new standard of care to prevent everolimus-induced oral mucositis?. Lancet Oncology, The, 2017, 18, 564-565.	5.1	1
195	¹⁸ F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clinical Cancer Research, 2017, 23, 3053-3060.	3.2	66
196	Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. Expert Review of Clinical Pharmacology, 2017, 10, 1169-1176.	1.3	9
197	Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Oncologist, 2017, 22, 1039-1048.	1.9	115
198	Antibodyâ€Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments. Targeted Oncology, 2017, 12, 719-739.	1.7	71

#	ARTICLE	IF	CITATIONS
199	High-Content Biopsies Facilitate Molecular Analyses and Do Not Increase Complication Rates in Patients With Advanced Solid Tumors. <i>JCO Precision Oncology</i> , 2017, 1, 1-9.	1.5	6
200	Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI). <i>Biomedical Optics Express</i> , 2017, 8, 555.	1.5	21
201	AKT1 low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 88.	2.2	25
202	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2141-2148.	0.8	283
203	Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. <i>Journal of Clinical Oncology</i> , 2017, 35, 2790-2797.	0.8	119
204	FGFR gene amplification and response to endocrine therapy in metastatic hormone receptor positive (HR+) breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1013-1013.	0.8	5
205	Tumor genomics and response to CDK 4/6 inhibitors for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1046-1046.	0.8	4
206	Phase (Ph) 2 stage 1 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor, in women with advanced AR+ triple-negative breast cancer (TNBC) or estrogen receptor (ER)+ BC: CLARITY-01.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1102-1102.	0.8	17
207	Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1514-1514.	0.8	3
208	Impact of PIK3CA tumor mutation on the association of aspirin or NSAID use and time to breast cancer recurrence.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1521-1521.	0.8	2
209	Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer: Phase 1b clinical trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1106-TPS1106.	0.8	1
210	Phase Ib study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant in women with metastatic or locally advanced/recurrent breast cancer (B2151009; NCT02684032).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1113-TPS1113.	0.8	2
211	A phase Ib, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS2606-TPS2606.	0.8	3
212	Therapy for chemopretreated metastatic urothelial cancer (mUC) with the antibody-drug conjugate (ADC) sacituzumab govitecan (IMMU-132).. <i>Journal of Clinical Oncology</i> , 2017, 35, 327-327.	0.8	5
213	Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology. <i>Oncotarget</i> , 2017, 8, 106167-106168.	0.8	25
214	Persistence of AKT1 low quiescent cancer cells after neoadjuvant chemotherapy in triple negative breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11579-11579.	0.8	0
215	Antibody-drug conjugates in breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 251-254.	0.3	1
216	Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1477.	3.4	259

#	ARTICLE	IF	CITATIONS
217	Metastatic Breast Cancer With <i>ESR1</i> Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital. <i>Oncologist</i> , 2016, 21, 1035-1040.	1.9	18
218	HER2 expression identifies dynamic functional states within circulating breast cancer cells. <i>Nature</i> , 2016, 537, 102-106.	13.7	335
219	Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women. <i>Mayo Clinic Proceedings</i> , 2016, 91, 71-80.	1.4	20
220	Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 1088-1088.	0.8	6
221	Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8559-8559.	0.8	4
222	Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9011-9011.	0.8	4
223	Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA509-LBA509.	0.8	3
224	Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA509-LBA509.	0.8	0
225	Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 586-586.	0.8	0
226	Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. <i>Discovery Medicine</i> , 2016, 21, 65-74.	0.5	59
227	Gene-Expression-Based Predictors for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 3418-3432.	0.7	24
228	Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. <i>Journal of Clinical Oncology</i> , 2015, 33, 3621-3627.	0.8	172
229	A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 1014-1014.	0.8	8
230	Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1016-1016.	0.8	6
231	Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2504-2504.	0.8	5
232	Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3546-3546.	0.8	5
233	Genomic landscape of primary breast cancer in black vs. white women and association with tumor recurrence.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6553-6553.	0.8	1
234	Isocitrate Dehydrogenase 1 (<i>IDH1</i>) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate. <i>Oncologist</i> , 2014, 19, 602-607.	1.9	61

#	ARTICLE	IF	CITATIONS
235	Solidifying Liquid Biopsies: Can Circulating Tumor Cell Monitoring Guide Treatment Selection in Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2014, 32, 3470-3471.	0.8	23
236	Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis. <i>Cell</i> , 2014, 158, 1110-1122.	13.5	1,960
237	Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. <i>Science</i> , 2014, 345, 216-220.	6.0	808
238	The Evolving Role of Circulating Tumor Cells in the Personalized Management of Breast Cancer: From Enumeration to Molecular Characterization. <i>Current Breast Cancer Reports</i> , 2014, 6, 146-153.	0.5	12
239	Precision medicine and personalized breast cancer: combination pertuzumab therapy. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 95.	0.4	13
240	Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 535-535.	0.8	16
241	A phase II study evaluating efficacy of zoledronic acid in prevention of aromatase inhibitor (AI)-associated musculoskeletal symptoms: The ZAP trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9615-9615.	0.8	0
242	Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6360-6370.	3.2	82
243	Hemodynamic signature of breast cancer under fractional mammographic compression using a dynamic diffuse optical tomography system. <i>Biomedical Optics Express</i> , 2013, 4, 2911.	1.5	32
244	Digoxin as an inhibitor of global hypoxia inducible factor-1 \pm (HIF1 \pm) expression and downstream targets in breast cancer: Dig-HIF1 pharmacodynamic trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS1144-TPS1144.	0.8	2
245	A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2013, 31, 219-219.	0.8	1
246	Phase II study of ruxolitinib in patients with pStat3+ breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS1134-TPS1134.	0.8	2
247	Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. <i>Journal of Clinical Oncology</i> , 2013, 31, 533-533.	0.8	0
248	Impact of single and dual neoadjuvant HER2-directed therapy on clinical outcomes among patients with HER2-positive breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 647-647.	0.8	0
249	Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. <i>Journal of Clinical Oncology</i> , 2013, 31, 145-145.	0.8	0
250	Neoadjuvant single and dual HER2 blockade among patients with localized HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 147-147.	0.8	1
251	Association of pathologic complete response following neoadjuvant chemotherapy with survival among young women with breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1122-1122.	0.8	38
252	Changes in patient-reported outcomes in women with breast cancer in a multicenter double-blind randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms (AIMSS).. <i>Journal of Clinical Oncology</i> , 2012, 30, 9103-9103.	0.8	0